Navigation Links
Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
Date:1/8/2014

CAMPBELL, Calif., Jan. 8, 2014 /PRNewswire/ -- Kalila Medical, a privately held medical device company focused on the development of next-generation steerable catheter technologies, today announced it has received CE mark approval for its Vado™ Steerable Introducer Sheath for vascular and intracardiac access including Atrial Fibrillation (AF) procedures.

"During an ablation procedure, it is extremely important to have precise control over placement of the ablation catheter," says Prof. Dr. Karl-Heinz Kuck, Director of Cardiology at St. Georg Hospital in Hamburg, Germany. "Currently available sheaths have poor torque response, so accurate positioning can be difficult and time-consuming. A steerable sheath with 1:1 torque response provides better navigation and tip positioning which allows me to create more precise, effective lesions."

AF is an irregular heartbeat that is caused by hypertension, heart disease and genetic predisposition and can result in symptoms such as shortness of breath, palpitations, confusion and weakness. If untreated, AF can result in a debilitating stroke. Newer approaches to treatment of AF include an endovascular approach using catheter-based ablation to interrupt pathways in the atria and prevent abnormal impulses from propagating. In 2012, there were 311,000 AF ablation procedures worldwide.

"The Vado steerable sheath addresses the existing shortcomings of currently available sheaths with its unique and patent-protected truVector™ technology that allows tip deflection without the use of pull wires. It's a simple yet innovative solution to creating a high performance, uniquely torqueable steerable sheath," commented Mike Dineen, President and CEO of Kalila Medical. "The current market for steerable sheaths in a-fib procedures exceeds $100 million and is growing at a rate of approximately 10% annually. We are pleased to move toward commercialization of the Vado Sheath in this high growth market."

Limited European market release of the Vado Sheath will commence in Q2 2014.

About Kalila Medical
Founded in 2010, Kalila Medical is a privately held medical device company, formed by Shifamed LLC, a Silicon Valley based medical device incubator. Kalila's first product, the VadoTM Steerable Sheath, is redefining precision and control with an innovative platform of specialized delivery and access catheters. The procedural benefits of Kalila's proprietary truVector™ technology can be leveraged across a growing number of endovascular applications including atrial fibrillation ablation, mitral valve repair, ASD/PFO closure, left atrial appendage closure, transseptal puncture, and LV lead placement.

For more information please visit www.kalilamedical.com.

MEDIA CONTACT:
Katie Arnold
SPRIG Consulting LLC
(408) 805-0520
katie@sprigconsulting.com


'/>"/>
SOURCE Kalila Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Puritan Medical Products erhält zwei neue Patente für beflockte Tupfer in Japan
2. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
3. Ensil Canada is Launching a New Medical Device: Publicly Traded Companies Are Invited to Acquire This Technology or Partner with Ensil Canada on the Marketing and Distribution of This New Device
4. Puritan Medical Products obtient deux nouveaux brevets au Japon pour ses écouvillons floqués
5. Puritan Medical Products Recebe Duas Novas Patentes Swab com Algodão no Japão
6. SonaCare Medical to Present at the 32nd Annual J.P. Morgan Healthcare Conference
7. Puritan Medical Products Awarded Two New Flocked Swab Patents in Japan
8. Aethlon Medical to Present at Biotech Showcase Investor Conference
9. Concord Medical Declares Special Dividend
10. Guam Regional Medical City moves forward with Allscripts to transform healthcare on Guam
11. Self-Care Medical Devices Market Expected to Reach USD 16.9 Billion Globally in 2019: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):